Valuation: Galapagos NV

Market Cap 154.73Cr 178.03Cr 178.03Cr 144.45Cr 132.61Cr 250.05Cr 17TCr 254.41Cr 1.7TCr 667.1Cr 8.46TCr 668.72Cr 653.91Cr 28TCr P/E 2026 *
-11x
P/E 2027 * -8.31x
Enterprise Value -44Cr -50Cr -50Cr -41Cr -37Cr -70Cr -4.78TCr -72Cr -479.98Cr -187.98Cr -2.38TCr -188.44Cr -184.27Cr -7.87TCr EV / Sales 2026 *
-30.6x
EV / Sales 2027 * -9.68x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 12/05/2025
Director of Finance/CFO 41 07/07/2025
Chief Operating Officer - 01/06/2026
Director TitleAgeSince
Director/Board Member 63 22/10/2019
Director/Board Member 49 07/10/2024
Director/Board Member 53 12/05/2025
Change 5-day change 1-year change 3-year change Capi.($)
-0.36%+0.14%-2.06%+14.33% 4.82TCr
-2.71%-2.99%+398.09%+472.12% 3.88TCr
-0.71%+9.45%+27.90%+7.89% 3.84TCr
-0.71%-3.72%+4.94%+52.45% 3.49TCr
-2.41%+1.96%+11.68%+38.17% 2.92TCr
-0.66%-2.73%+35.50%+122.17% 1.6TCr
-0.19%-3.93% - - 1.6TCr
-0.62%+1.23%+2.76%+15.05% 1.35TCr
-3.15%-6.14%-4.82%-36.90% 1.22TCr
Average -1.28%-0.66%+59.25%+85.66% 2.75TCr
Weighted average by Cap. -1.23%+0.15%+75.56%+103.60%

Financials

2026 *2027 *
Net sales 1.42Cr 1.64Cr 1.64Cr 1.33Cr 1.22Cr 2.3Cr 156.18Cr 2.34Cr 16Cr 6.14Cr 78Cr 6.15Cr 6.02Cr 256.89Cr 4.61Cr 5.3Cr 5.3Cr 4.3Cr 3.95Cr 7.45Cr 505.45Cr 7.58Cr 51Cr 20Cr 252.06Cr 20Cr 19Cr 831.39Cr
Net income -81Cr -93Cr -93Cr -76Cr -69Cr -131.01Cr -8.89TCr -133.3Cr -892.46Cr -349.53Cr -4.43TCr -350.38Cr -342.62Cr -15TCr -24Cr -27Cr -27Cr -22Cr -20Cr -38Cr -2.61TCr -39Cr -261.78Cr -102.53Cr -1.3TCr -102.78Cr -100.5Cr -4.29TCr
Net Debt -198.33Cr -228.2Cr -228.2Cr -185.16Cr -169.98Cr -320.51Cr -22TCr -326.1Cr -2.18TCr -855.08Cr -11TCr -857.16Cr -838.17Cr -36TCr -199.35Cr -229.38Cr -229.38Cr -186.12Cr -170.86Cr -322.17Cr -22TCr -327.78Cr -2.19TCr -859.51Cr -11TCr -861.6Cr -842.51Cr -36TCr
Logo Galapagos NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B